Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?
Titel:
Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?
Auteur:
Di Maio, V.C. Armenia, D. Cento, V. Di Paolo, D. Tontodonati, M. Micheli, V. Bellocchi, M.C. Carioti, L. De Leonardis, F. Continenza, F. De Luca, F. Polilli, E. Manunta, A. Magni, C. Antonucci, F.P. Aragri, M. Sarrecchia, C. Bertoli, A. Lenci, I. Francioso, S. Vecchiet, J. De Maria, A. Picciotto, A. Nosotti, L. Bruno, S. Puoti, M. Babudieri, S. Mura, M.S. Andreoni, M. Rizzardini, G. Parruti, G. Angelico, M. Perno, C.F. Ceccherini-Silberstein, F.